Drugs / CEFILAVANCIN
CEFILAVANCIN
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00442832 | Dec 2006 → May 2007 | staphylococcal infection | Theravance Biopharma | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEFILAVANCIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297645 ↗ |
| Known as | Cefilavancina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297645 ↗ |
| Known as | Cefilavancine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297645 ↗ |
| Known as | TD-1792 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00442832 ↗ |
| Route | Intravenous | “2 mg/kg/day IV” NCT00442832 ↗ |